Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00354835 |
Recruitment Status : Unknown
Verified December 2016 by Children's Oncology Group.
Recruitment status was: Active, not recruiting
First Posted : July 20, 2006
Results First Posted : July 25, 2017
Last Update Posted : October 27, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Adult Malignant Mesenchymoma Adult Rhabdomyosarcoma Childhood Alveolar Rhabdomyosarcoma Childhood Botryoid-Type Embryonal Rhabdomyosarcoma Childhood Embryonal Rhabdomyosarcoma Childhood Malignant Mesenchymoma Non-Metastatic Childhood Soft Tissue Sarcoma Stage I Adult Soft Tissue Sarcoma Stage II Adult Soft Tissue Sarcoma Stage III Adult Soft Tissue Sarcoma Untreated Childhood Rhabdomyosarcoma | Drug: Irinotecan Hydrochloride Biological: Dactinomycin Drug: Cyclophosphamide Drug: Vincristine Sulfate Radiation: Radiation Therapy Other: Laboratory Biomarker Analysis Other: Questionnaire Administration | Phase 3 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 481 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS) |
Study Start Date : | December 2006 |
Actual Primary Completion Date : | December 2014 |

Arm | Intervention/treatment |
---|---|
Active Comparator: VAC
Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
|
Biological: Dactinomycin
Given IV
Other Name: Lyovac Cosmegen Drug: Cyclophosphamide Given IV Drug: Vincristine Sulfate Given IV
Other Names:
Radiation: Radiation Therapy Undergo radiotherapy
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Other: Questionnaire Administration Ancillary studies |
Experimental: VAC Alternating with VI
Patients receive VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; and irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
|
Drug: Irinotecan Hydrochloride
Given IV Biological: Dactinomycin Given IV
Other Name: Lyovac Cosmegen Drug: Cyclophosphamide Given IV Drug: Vincristine Sulfate Given IV
Other Names:
Radiation: Radiation Therapy Undergo radiotherapy
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Other: Questionnaire Administration Ancillary studies |
- Event Free Survival (EFS) [ Time Frame: 4 years ]Probability of no relapse, secondary malignancy, or death after 4 year in the study
- Response Rate (RR) [ Time Frame: Reporting Period 1 (Weeks 1 - 15) ]Proportion of patients with complete or partial response. Complete Response (CR): Complete disappearance of the tumor confirmed at > 4 weeks; Partial Response (PR): At least 64% decrease in volume compared to the baseline; Overall Response (OR) = CR + PR.
- Overall Survival (OS) [ Time Frame: 4 years ]Probability of being alive after 4 years in the study.
- Event Free Survival (EFS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison [ Time Frame: 4 years ]Compare 4-year EFS using eligible participants only to the historical rate of 0.65 with IRSI-V. The 4-year EFS is probability of no relapse, secondary malignancy, or death after 4 years in the study. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.65.
- Local Failure [ Time Frame: 2 years ]Compare 2-year local failure rate to the historical rate of 0.13 with IRSI-V. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.13.
- Overall Survival (OS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison [ Time Frame: 4 years ]Compare 4-year OS using eligible participants only to the historical rate of 0.70 with IRSI-V. The 4-year OS is probability of being alive after 4 years in the study. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.70.
- Incidence of Toxicity [ Time Frame: Up to 15 weeks ]Grade 3 or 4 nausea, diarrhea, dehydration, radiation dermatitis, mucositis due to radiation. Severe and undesirable adverse event is considered as grade 3; Life-threatening or disabling adverse event is grade 4. Grade 4 is worse than grade 3.
- Acute and Late Effects of VAC as Delivered on This Study to D9803 VAC [ Time Frame: Up to 43 weeks ]The toxicity rates will be estimated for each phase and course of treatment, and will be compared to the fixed rates under D9803 using one-sided lower confidence intervals for a single proportion without adjustment for multiple comparisons.
- Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 4 [ Time Frame: 4 years ]4-year EFS (probability of no relapse, secondary malignancy, or death after 4 years in the study).
- Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 15 [ Time Frame: 4 years ]4-year EFS (probability of no relapse, secondary malignancy, or death after 4 years in the study)
- Incidence of Toxicity Related to VI Treatment in Patients With UGT1A1 Genotype [ Time Frame: Weeks 4-9 (the first exposure to VI) ]Severe and undesirable adverse event is considered as grade 3; Life-threatening or disabling adverse event is grade 4. Grade 4 is worse than grade 3.
- Toxicity With CYP2B6 Genotypes [ Time Frame: During the study ]Incidence of toxicity related to VAC treatment in patients with CYP2B6 genotypes.
- Toxicity With GSTA1 and CYP2C9 Genotypes [ Time Frame: During the study ]Incidence of toxicity related to VAC treatment in patients with GSTA1 and CYP2C9 genotypes.
- Event Free Survival (EFS) by PAX Status [ Time Frame: 4 years ]
- Incidence of Bladder Dysfunction [ Time Frame: 3-6 years after enrollment ]Number of patients with a summary score greater than 8.5

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 49 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with newly diagnosed embryonal RMS, botryoid or spindle cell variants of embryonal RMS, ectomesenchymoma, or alveolar RMS are eligible for this study
- Enrollment on COG-D9902 to confirm local histologic diagnosis with central pathology review is required for all patients
- Patients may be enrolled on ARST0531 and start protocol treatment prior to receipt of central pathology review results
-
Patient must have Intermediate-risk RMS defined as:
- Embryonal, botryoid, or spindle cell RMS, or ectomesenchymoma: stage 2 or 3 and group III OR
- Alveolar RMS: stage 1-3 and group I-III
- Staging ipsilateral retroperitoneal lymph node dissection (SIRLND) is required for all patients >= 10 years of age with paratesticular tumors and for patients < 10 years with clinically or radiographically involved lymph nodes (except when extensive lymph node involvement, defined as two or more lymph nodes > 2 cm in dimension, is identified by imaging studies)
- Regional lymph node sampling or sentinel lymph node procedure is required for histologic evaluation in patients with extremity tumors
- Clinically or radiographically enlarged nodes should be sampled for histologic evaluation
- Detection of metastasis by optional FDG PET (not required for study enrollment); FDG PET may detect abnormalities suggestive of metastasis not identified by bone scan, computed tomography (CT), or bone marrow aspiration/biopsy; the prognostic significance of FDG PET-detected abnormalities is not clear; FDG PET-detected abnormalities MUST be confirmed to be metastases by an additional imaging modality (such as magnetic resonance imaging [MRI] or CT) OR pathologic confirmation; unless FDG PET abnormalities are confirmed by another imaging modality or biopsy, FDG PET abnormalities will NOT be considered evidence of metastasis
- Patients must have a performance status of 0, 1, or 2; the Lansky performance score should be used for patients < 16 years and the Karnofsky performance score for patients >= 16 years
- Patients who have received prior chemotherapy (excluding steroids) or radiation therapy, except for patients transferring from ARST0331 (low-risk study), are not eligible
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:
- 1 month to < 6 months: 0.4 mg/dL
- 6 months to < 1 year: 0.5 mg/dL
- 1 to < 2 years: 0.6 mg/dL
- 2 to < 6 years: 0.8 mgt/dL
- 6 to < 10 years: 1 mg/dL
- 10 to < 13 years: 1.2 mg/dL
- 13 to < 16 years: 1.5 mg/dL (males) or 1.4 mg/dL (females)
- >= 16 years: 1.7 mg/dL (males) or 1.4 mg/dL (females)
- Patients with urinary tract obstruction by tumor must meet the renal function criteria AND must have unimpeded urinary flow established via decompression of the obstructed portion of the urinary tract
- Total bilirubin =< 1.5 x upper limit of normal for age
- Peripheral absolute neutrophil count (ANC) >= 750/uL
- Platelet count >= 75,000/uL (transfusion independent)
- No evidence of uncontrolled infection
- Patients must be able to undergo radiation therapy, if necessary, as specified in the protocol
- Female patients of childbearing potential must have a negative pregnancy test
- Female patients who are breast feeding must agree to stop breast feeding
- Sexually active patients of childbearing potential must be willing to use effective contraception during therapy and for at least 1 month after treatment is completed
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00354835

Principal Investigator: | Douglas Hawkins, MD | Children's Oncology Group |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Children's Oncology Group |
ClinicalTrials.gov Identifier: | NCT00354835 |
Other Study ID Numbers: |
ARST0531 NCI-2009-00427 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) COG-ARST0531 ( Other Identifier: Children's Oncology Group ) CDR0000487560 ( Other Identifier: ClinicalTrials.gov ) ARST0531 ( Other Identifier: Children's Oncology Group ) ARST0531 ( Other Identifier: CTEP ) U10CA098543 ( U.S. NIH Grant/Contract ) U10CA180886 ( U.S. NIH Grant/Contract ) |
First Posted: | July 20, 2006 Key Record Dates |
Results First Posted: | July 25, 2017 |
Last Update Posted: | October 27, 2020 |
Last Verified: | December 2016 |
Sarcoma Rhabdomyosarcoma Mesenchymoma Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma, Embryonal Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Myosarcoma Neoplasms, Muscle Tissue Neoplasms, Complex and Mixed Dactinomycin Cyclophosphamide Irinotecan Vincristine |
Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Antineoplastic Agents, Phytogenic Tubulin Modulators Antimitotic Agents |